Key Takeaways
- Record revenue, 11th straight quarter: Growth was balanced across all three verticals, with Plant-2 extension and injectable ramp-up now contributing meaningfully.
- Injectable facility is behind plan: Management confirmed the injectable plant is running behind its intended timeline and numbers, though commercial supplies are ramping up across both CDMO and Trade Generics.
- ESOP charge arrives, margin roadmap withheld: A INR1.2 crore non-cash ESOP charge hit the quarter, and management declined to provide any timeline or target for reaching 15% EBITDA margins.
- Inorganic appetite is real and urgent: The company is actively hunting for acquisitions, willing to pay a premium, partly because available injectable plants are too old to meet new Schedule M standards.
- What to watch next quarter: Whether Plant-6 commissioning stays on track for FY26, the pace of injectable customer approvals and commercial ramp-up, and any inorganic move.
Injectable Ramp-Up: Behind Schedule, Central to the Story
- Admitted delay: Management confirmed the injectable plant is running a little behind in timeline and numbers compared to where they would have wanted to be.
- Progress is real but gradual: Several products across ampoules, vials and lyophilized vials have been commercialized, with stability data done and regular orders coming in. Customer approvals are being gained and commercial supplies are ramping up across both CDMO and Trade Generics verticals.
- Export is the long game: Management stated the injectable facility has to focus on export business in the long term, with product dossiers under preparation and efforts underway to open new geographies.
- Capacity trigger for next dosage form: The company intends to add a new dosage form organically once injectables reach near peak capacity utilization, unless a suitable inorganic opportunity is found sooner.
- Dosage form sequencing is deliberate: Management does not see adding too many dosage forms at once as a good strategy, citing the learning curve each one demands across R&D, stability batches, approvals and customer plant audits. They want each dosage form to roll on its own momentum before adding another.
Hitesh Windlass: "The reason we did injectables is because a lot of the available injectable plants from an inorganic perspective are very, very old infrastructure. They're not even meeting the GMP requirements that have come in new Schedule M and even looking further."
Inorganic Strategy: Active Search, Premium Tolerated
- Actively hunting: The company is very actively looking at various opportunities and is open to acquiring an asset even at a premium if it sees good synergy and potential where fixing a critical problem is not required.
- Injectable M&A is unattractive: Management explained the organic injectable route was chosen because available injectable plants for acquisition are mostly very old infrastructure that fail to meet new Schedule M GMP requirements.
- Oral solids stay organic: On oral solids, the company wants to continue the organic path because it can bring capacity in at much lower potential cost and ramp it up quickly.
- New dosage form via M&A or build: If no external acquisition is found by the time injectables near peak capacity, the company intends to pick one dosage form and build it on its own.
Komal Gupta: "We are very much open and very actively looking at various opportunities and would be open to acquire an asset even at a premium if we see good synergy with our business and potential where we don't have to do the fixing of a very critical problem."
Trade Generics & CDMO: Structural Tailwinds, Market Share Play
- Organized shift validated: Large pharma companies that traditionally ignored trade generics have announced entries, validating the shift from unorganized to organized trade generics. Management sees both competition and opportunity in this.
- Outperformance attributed to quality moat: Management credits outperformance versus IPM volume growth to being a well-organized, quality-compliant player with strong regulatory standing, which gives an advantage against smaller players.
- CDMO share built methodically: Growth has come from building the leadership and business development teams, consistently adding customers, reducing customer concentration, expanding the product portfolio, adding geographies for Trade Generics, and adding institutions without regard to low initial contribution.
- Fixed-dose combination trend: In chronic diseases like diabetes and cardiovascular, multidrug treatment has proven better response for the Indian genotype, and marketing company influence on physicians is also a factor driving FDC demand.
- CDMO market sizing is opaque: Management stated no published data exists for the CDMO total addressable market, only thumb-rule estimates based on the percentage of Indian pharma market outsourced, which they never state as a number.
Exports: Early-Stage Build-Out
- Growth reflects expanding footprint: Export growth is driven by an increasing footprint across semi-regulated geographies.
- Team and dossier build underway: The export business development team has been expanded, more people are being sought, and injectable product dossiers are under preparation for filing. Efforts are also being made to open other markets geographically.
- Growth rate not disclosed: Management declined to break down a sustainable annual growth rate for exports, citing quarterly volatility, but called it an important vertical where growth is expected and ample opportunities exist.
ESOPs & People: Investment Framed as Strategic Necessity
- ESOP 2025 scheme launched: Grants were awarded in mid-September covering almost 100 people across various management levels. The scheme has two components: performance-related ESOPs linked to deliverable KPIs (financial and operational) and retention-related ESOPs.
- Non-cash charge: INR1.2 crore of ESOP expenditure was reflected in the quarter's financials, and the company does not expect the accounting impact to go away or materially get lower.
- Strike price at face value: ESOPs were granted at a strike price of INR5 (face value). Management explained the philosophy and retention rationale but did not address why a market-linked strike price was not used.
- Forfeiture pool recycles: If employees resign or are let go for lack of performance, unvested ESOPs return to the pool.
- KPIs are balanced-scorecard: Company-level KPIs include revenue growth and operational efficiency; departmental KPIs apply to lower-level employees, with annual HOD KPIs and internal assessments.
Hitesh Windlass: "If you look at how much we have invested in capex since we came to public market, we have an injectable plant. We added a Plant-2 extension. We are now going for Plant-6. We are talking about doing inorganic. So this, if you don't do, then the strategy remains half baked."
Margins: Investment Phase, No Roadmap Offered
- ESOP charge is a new line item: The INR1.2 crore non-cash ESOP charge hit the P&L this quarter and is expected to persist.
- Management expects improvement but won't quantify: Management stated it expects overall margin improvement for the company, but added that when and how much remains to be seen.
- 15% EBITDA margin question deflected: When asked directly for a roadmap or timeline to reach 15% EBITDA margins given ESOP and injectable facility investments, management declined, stating they never gave guidance.
- Inventory days dropped on GST change: Inventory days fell from 39 to 29 days as the company held minimum inventory for critical products and did only necessary purchases for revenue it was sure about delivering. This should normalize.
- No revenue lost from GST change: The company aligned properly with customers, got MRP updates, and delivered everything planned in September.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Plant-6 commissioning | Facility to be commissioned | Within FY26 |
| New dosage form addition | Add one dosage form organically if no inorganic deal found | When injectables near peak capacity utilization |
| Export dossier filings | Injectable product dossiers under preparation, will be filed | Not specified |
| Inventory days normalization | Inventory days should return to normal levels after GST-driven drop to 29 days | Not specified |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue from operations | ₹222 cr, +19% YoY |
| H1 FY26 revenue from operations | ₹432 cr, +19% YoY |
| EBITDA | ₹29 cr |
| EBITDA margin (excl. ESOP impact) | 13.5% |
| PAT | ₹18 cr |
| H1 FY26 PAT | ₹35 cr |
| Gross margin improvement | 68 bps YoY |
| H1 FY26 EPS | ₹16.91, +21% YoY |
| Generic Formulations CDMO growth | 18% YoY (Q2 and H1 FY26) |
| Trade Generics & Institutional growth | 24% YoY in Q2 FY26, 25% in H1 FY26 |
| Exports growth | 13% YoY in Q2 FY26, 23% in H1 FY26 |
| Indian pharma market growth | 7.7% YoY, volume decline of 0.2% |
| ESOP non-cash expenditure | ₹1.2 cr in Q2 FY26 |
| Inventory days | 29 days, down from 39 days due to GST caution |
| Revenue from India | 94% of total revenues |